Zim Laboratories Ltd
ZIMLAB
Company Profile
Business description
Zim Laboratories Ltd is a pharmaceutical company. The company is mainly engaged in the manufacturing of formulation drugs and pre-formulation ingredients. Geographically, the group has a business presence in India and other countries, of which key revenue is derived from Outside India. The products offered by the company are Ondansetron, Melatonin, Nicotine, Vitamin D3, and others. The majority of its revenue is derived from the sale of pharmaceutical goods.
Contact
Nelson Square, Chhindwara Road
Sadoday Gyan, Ground Floor
Opposite NADT
NagpurMH440 013
INDT: +91 7122981960
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2027
Employees
577
Stocks News & Analysis
stocks
Undervalued ASX share retains wide moat rating despite regulatory pressures
Proposed price regulation impacts our fair value.
stocks
Our top ASX picks in every sector
These companies are our favourite choices for investors wanting to boost Aussie equity exposure.
stocks
Tesla: Shares fall as deliveries come in below consensus
Long-term growth less reliant on auto sales.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,921.20 | 21.50 | 0.24% |
| CAC 40 | 7,908.74 | 53.65 | -0.67% |
| DAX 40 | 22,921.59 | 246.49 | -1.06% |
| Dow JONES (US) | 46,584.46 | 85.42 | -0.18% |
| FTSE 100 | 10,348.79 | 87.50 | -0.84% |
| HKSE | 25,116.53 | 177.50 | -0.70% |
| NASDAQ | 22,017.85 | 21.51 | 0.10% |
| Nikkei 225 | 53,429.56 | 15.88 | 0.03% |
| NZX 50 Index | 13,069.66 | 243.79 | 1.90% |
| S&P 500 | 6,616.85 | 5.02 | 0.08% |
| S&P/ASX 200 | 8,728.80 | 43.80 | 0.50% |
| SSE Composite Index | 3,919.29 | 29.27 | -0.74% |